Eupraxia Pharmaceuticals Inc. (EPRX) vs Greenwich LifeSciences, Inc. (GLSI)
A side-by-side comparison of Eupraxia Pharmaceuticals Inc. and Greenwich LifeSciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EPRX
Eupraxia Pharmaceuticals Inc.
$7.73HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
GLSI
Greenwich LifeSciences, Inc.
$16.19HealthcareDelayed quote: Oct 6, 2026, 3:34 PM EDT
Total return — EPRX vs GLSI
growth of $100 · dividends reinvested · last 2yEPRX +162.7% (+62.1%/yr)GLSI -2.7% (-1.4%/yr)EPRX compounded faster over this window
EPRX GLSI
EPRX vs GLSI: by the numbers
- •EPRX is the larger company ($259M vs $238M market cap).
Metrics side by side
Valuation
| Metric | EPRX | GLSI |
|---|---|---|
| P/B ratio | 2.55 | 76.24 |
Profitability
| Metric | EPRX | GLSI |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -38.33% | -695.56% |
| ROIC | -43.56% | -701.55% |
Growth (annualized)
| Metric | EPRX | GLSI |
|---|---|---|
| Total return CAGR (5Y) | N/A | -14.84% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.